{"entity":{"id":"da-aducanumab","kind":"drug","name":"Aducanumab","aka":[],"tldr":"Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option.","summary":"ENGAGE did not meet its primary endpoint as designed. The product is listed so a past approval is not confused with present availability.","status":"withdrawn","asOf":"2026-09-21","links":[{"label":"FDA withdrawn accelerated approvals","url":"https://www.fda.gov/drugs/accelerated-approval-program/withdrawn-non-malignant-hematological-neurological-and-other-disorder-indications-accelerated"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["da-biogen"],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-engage"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Aduhelm","modality":"mAb","mechanism":"Amyloid-beta–directed antibody. The US Alzheimer’s indication was withdrawn in 2024.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/da-aducanumab/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}],"company":[{"id":"da-biogen","kind":"company","name":"Biogen","route":"/companies/da-biogen/"}],"trial":[{"id":"da-trial-engage","kind":"trial","name":"ENGAGE","route":"/trials/da-trial-engage/"}],"technology":[{"id":"da-tech-anti-amyloid-mab","kind":"technology","name":"Anti-amyloid antibodies","route":"/technologies/da-tech-anti-amyloid-mab/"}],"roadmap":[{"id":"da-roadmap-anti-amyloid","kind":"roadmap","name":"Anti-amyloid medicines","route":"/roadmaps/da-roadmap-anti-amyloid/"}]}}